Welcome to HDMZ Connect, our monthly newsletter delivering the latest trends shaping science, biotech and healthcare — showcasing work that drives revenue, reputation, and investment for compelling brands — and offering an inside look at the award-winning culture behind it all.

Miriam Hyman (Senior Content Strategist) breaks down how to address the diverse perspectives across the oncology landscape. Where patients want clear answers, clinicians demand clinical outcomes data, and clinical developers look for collaborative research partners. To scale, diagnostics companies must invest in connecting with their audiences as rigorously as they invest in their science.

Inspiring Advances in Bioprocessing

To support Repligen’s continuous market leadership, HDMZ worked closely with the talented Repligen digital team to craft a strategic website refresh that aligns their digital identity with their global stature. We collaborated to deliver a complete UX and visual overhaul that enhances the user journey and supports future expansion, all while keeping core infrastructure seamless.

Why CRISPR is the Boldest Bet Yet for Alzheimer's Research 

For decades, Alzheimer’s drug development meant getting comfortable with failure. While anti-amyloid therapies show modest benefits, they act as maintenance tools rather than definitive fixes. Mohana Ray (Scientific Director) explores the paradigm shift to CRISPR, using precise gene editing to correct the disease's underlying genetic architecture.

Many PR campaigns fall into the trap of executing arbitrary tactics without a clear objective. Katy Steele (Senior Content Strategist) explores how we use our proprietary Future State Strategy™ framework to bring absolute intentionality to everyday PR. By reverse-engineering a data-informed plan from your long-term business goals, we ensure every pitch actually moves the needle, builds deeper trust with journalists, and aligns your metrics directly with corporate growth.